<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1023">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04348409</url>
  </required_header>
  <id_info>
    <org_study_id>NITFQM0320OR</org_study_id>
    <nct_id>NCT04348409</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19</brief_title>
  <official_title>Proof of Concept, Multicentre, Parallel, Randomized, Double-blind Clinical Trial to Assess the Safety and Efficacy of Nitazoxanide 600 mg Compared to Placebo in the Treatment of Hospitalized Patients With COVID-19 in Moderate Condition.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azidus Brasil</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Farmoquimica S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Vera Cruz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Casa de Saúde - Vera Cruz - Campinas - SP - Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro de Genomas - UNIFESP</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emilio Ribas Institute of Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azidus Brasil</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a proof of concept study to evaluate the efficacy of nitazoxanide (600 mg BID) to
      treat hospitalized patients with moderate COVID-19.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a proof of concept study to evaluate the efficacy of nitazoxanide (600 mg BID) to
      treat hospitalized patients with moderate COVID-19.

      The aim is to demonstrate a decrease in hospital related complications among patients who are
      hospitalized with moderate COVID-19 by treating them with nitazoxanide for 7 days on top of
      standard care compared to patients who receive standard care and placebo.

      Patients hospitalized with confirmed diagnosis of COVID-19 will be randomized to receive
      either nitazoxanide or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 25, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized to receive either nitazoxanide or placebo (1:1).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Viral load</measure>
    <time_frame>day 1, 4, 7, 14 and 21</time_frame>
    <description>PCR will be done to evaluate the change in viral load</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evolution of acute respiratory syndrome</measure>
    <time_frame>21 days</time_frame>
    <description>Time to wean off oxygen supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Condition</measure>
    <time_frame>21 days</time_frame>
    <description>WHO Ordinal Scale for Clinical Improvement that measures illness severity over time (0=uninfected; ambulatory, no limitation of activities=1; ambulatory, limitation of activities=2, hospitalized no oxygen therapy=3; hospitalized oxygen by mask or nasal prongs=4; hospitalized non invasive ventilation or high-flow oxygen=5; hospitalized intubation or mechanical ventilation=6; hospitalized ventilation + additional organ support=7; death=8)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital discharge</measure>
    <time_frame>21 days</time_frame>
    <description>Time to be discharged from hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of mortality within 21-days</measure>
    <time_frame>21 days</time_frame>
    <description>Evaluation of change in acute respiratory syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need of mechanical ventilation</measure>
    <time_frame>21 days</time_frame>
    <description>Evaluation of change in acute respiratory syndrome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>nitazoxanide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive nitazoxanide 600 mg BID for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive placebo BID for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitazoxanide Tablets</intervention_name>
    <description>Patients will receive nitazoxanide 600 mg BID for 7 days</description>
    <arm_group_label>nitazoxanide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will receive placebo BID for 7 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent from patient or legal representative.

          2. Male or female, aged ≥ 18 years;

          3. Laboratory confirmation of 2019-nCoV infection by reverse-transcription polymerase
             chain reaction (RT-PCR) from any diagnostic sampling source;

          4. Signs of respiratory failure requiring oxygen therapy

          5. Hospitalized for up to 36h with non-invasive ventilation

          6. Negative result for pregnancy test (if applicable).

        Exclusion Criteria:

          1. Participating in another RCT in the past 12 months;

          2. Known allergy to nitazoxanide

          3. Severely reduced LV function;

          4. Severely reduced renal function;

          5. Pregnancy or breast feeding;

          6. Use of hydroxychloroquine and/or azithromycin in the past 15 days;

          7. Any other clinical condition which, in the opinion of the principal investigator,
             would not allow safe completion of the protocol and safe administration of the
             investigational products
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Florentino de Araujo Cardoso Filho, MD, PhD</last_name>
    <phone>+55 19 991232882</phone>
    <email>florentino.cardoso@hospitalcare.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luciana Ferrara</last_name>
    <phone>+55 19 981428814</phone>
    <email>luciana.ferrara@azidusbrasil.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Vera Cruz</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florentino de Araujo Cardoso Filho</last_name>
      <email>florentino.cardoso@hospitalcare.com.br</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Genomas</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Diaz, MD, PhD</last_name>
      <phone>+55 11 991090445</phone>
      <email>rsdiaz@catg.om.br</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Emílio Ribas</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sérgio Cimerman, MD, PhD</last_name>
      <phone>+55 11 98377-7272</phone>
      <email>scimerman@uol.com.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 3, 2020</study_first_submitted>
  <study_first_submitted_qc>April 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2020</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitazoxanide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>It is believed that after the data analysis and presentation to the National Commission on Research Ethics, all data of the study will become public.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

